Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

marketing rights for XARELTO®, and is supported by the Bayer HealthCare U.S. sales force.

For more information about XARELTO®, visit www.xarelto-us.com. The XARELTO® CarePath™ Support Program is a resource designed for health care providers, patients and caregivers. Visit www.xareltocarepath.com or call 1-888-XARELTO to learn more about the XARELTO® CarePath™ resources focused on access, education and adherence.

Important Safety Information

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

  • For people taking XARELTO® for atrial fibrillation:
    People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO® lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO®, you may have increased risk of forming a clot in your blood.
    Do not stop taking XARELTO® without talking to the doctor who prescribes it for you. Stopping XARELTO® increases your risk of having a stroke.
    If you have to stop taking XARELTO®, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming.
  • XARELTO® can cause bleeding, which can be serious, and rarely may lead to death. This is because XARELTO® is a blood thinner medicine that reduces blood clotting. While you take XARELTO® you are likely to bruise more easily and it may take longer for bleeding to stop

You may have a higher risk of bleeding if you take XARELTO<
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... DC (PRWEB) August 21, 2014 Atlantic ... publisher of ACO Business News and The AIS Report ... with the Blue Cross Blue Shield Association or its ... of the latest report in AIS’s Management Insight Series. ... offers case studies of two insurers — Horizon Healthcare ...
(Date:8/21/2014)... Only 20 percent of healthcare providers currently meet ... according to a new report . , Over 200 ... request from Smart Data pioneer peer60. Participants reported ... violate privacy laws in many states. , “Reaching the ACA’s ... clinics are failing to do so in part because it ...
(Date:8/21/2014)... Consilium Staffing, Your Partner in Locum Tenens, ... in response to the President’s landmark VA hospital reform ... the Department of Veterans Affairs to hire more doctors. ... one hundred fifty medical centers nationwide, and has been ... awaiting treatment, including vets from the Vietnam War, Iraq, ...
(Date:8/21/2014)... 2014 Inc. magazine ranked Centurion Service ... an exclusive ranking of the nation's fastest-growing private companies. ... most important segment of the economy—America’s independent entrepreneurs. Companies ... Zillow, and many other well-known names gained early exposure ... proud to have been named to the Inc. 5000 ...
(Date:8/21/2014)... Centre, NY (PRWEB) August 21, 2014 ... law firm with over 25 years of experience advocating ... prescription drugs and defective medical devices, announces the launch ... information to those women who believe they have been ... site offers valuable information about the severe adverse side ...
Breaking Medicine News(10 mins):Health News:New AIS Report Highlights Two Case Studies of Bundled Payment Models 2Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Consilium Staffing Providing Locum Tenens in Response to VA Hospital Reform Legislation 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2
... ANGELES, Nov. 25 The Black AIDS Institute recently held ... , The new Board Members are a highly diverse group ... health programs, editorial, and business entrepreneurship. The Board also comes ... and gay Black men and women, some living with HIV ...
... significant survival benefit from adjuvant tamoxifen among patients ... of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), ... 25 in the Journal of the National ... carcinomas are resistant to tamoxifen. Preclinical studies have ...
... fight rheumatoid arthritis, could help newly diagnosed diabetics, study ... drug commonly used to treat non-Hodgkin,s lymphoma and rheumatoid ... newly diagnosed with type 1 diabetes. , The drug, ... own insulin, even though the disease had destroyed some ...
... CDC sees few signs of trouble with the H1N1 ... ongoing H1N1 swine flu pandemic may be driving a ... U.S. health official said Wednesday. , "We are seeing ... Dr. Anne Schuchat, director of the National Center for ...
... the body on a carefully engineered, fingernail-sized implant is ... report this week in the journal Science Translational ... and immunologists at Harvard University, uses plastic disks impregnated ... reprogram the mammalian immune system to attack tumors. The ...
... parts of speech colored perception of sounds , WEDNESDAY, Nov. ... their ears, but also with their skin, new research shows. ... certain types of speech actually helped people decipher sounds better, ... to show whether we could use tactile information in this ...
Cached Medicine News:Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
Inquire...
... design makes positioning quick and ... wheelchair accessible and can support ... lbs. The AIT-8B provides stable ... units and includes a motorized ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... FDA-Approved BV-1000 is the worlds ... system. With the BV-1000, Topcon ... of refracting instruments. This innovative ... binocular auto-refractor, auto-keratometer, automatic chart ...
Medicine Products: